Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)

Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Shih Ee Goh, Saumya Shekhar Jamuar, Siew Eng Chua, Derrick Chen Kuan Yeo, Jerome Hern Yee Goh, Chee Hon Chin, Mohamed Zakir Karuvetil, Ee Lian Lee, Daniel Shuen Sheng Fung, Giles Ming Yee Tan
Format: Article
Language:English
Published: Academy of Medicine Singapore 2024-12-01
Series:Annals, Academy of Medicine, Singapore
Online Access:https://annals.edu.sg/pharmacogenomics-in-psychiatry-practice-recommendations-from-an-asian-perspective-2024/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841544079021703168
author Shih Ee Goh
Saumya Shekhar Jamuar
Siew Eng Chua
Derrick Chen Kuan Yeo
Jerome Hern Yee Goh
Chee Hon Chin
Mohamed Zakir Karuvetil
Ee Lian Lee
Daniel Shuen Sheng Fung
Giles Ming Yee Tan
author_facet Shih Ee Goh
Saumya Shekhar Jamuar
Siew Eng Chua
Derrick Chen Kuan Yeo
Jerome Hern Yee Goh
Chee Hon Chin
Mohamed Zakir Karuvetil
Ee Lian Lee
Daniel Shuen Sheng Fung
Giles Ming Yee Tan
author_sort Shih Ee Goh
collection DOAJ
description Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements. This review aims to examine recent updates in this field and provide a contextualised summary and recommendations for Asian populations in order to guide healthcare professionals in psychiatric practice. Method: A review of recent literature about current evidence and guidelines surrounding pharmacogenomics in psychiatric practice was carried out with particular attention paid to literature evaluating Asian populations. The Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework was applied. Consensus meetings comprising workgroup psychiatrists from the public and private sectors were held prior to arriving at the key recommendations. Results: Pharmacogenomic testing should be mainly limited to drug-gene pairs with established clinical evidence, such as antidepressants and CYP2C19/CYP2D6. Direct-to-consumer pharmacogenomic panels that assay multiple genes and analyse them via proprietary algorithms, are not presently recommended in Singapore’s psychiatric setting due to inconclusive evidence on clinical outcomes. Conclusion: Pharmacogenomic testing in psychiatry is not recommended as standard clinical practice. Exceptions may include concerns about drug concentrations or potential severe adverse drug reactions. Studies investigating newly identified drug-gene associations, and clinical effectiveness and cost-effectiveness of utilising pharmacogenomic testing in psychiatry is encouraged.
format Article
id doaj-art-662047bed73a411e81374f893ae7ec61
institution Kabale University
issn 2972-4066
language English
publishDate 2024-12-01
publisher Academy of Medicine Singapore
record_format Article
series Annals, Academy of Medicine, Singapore
spelling doaj-art-662047bed73a411e81374f893ae7ec612025-01-13T02:57:28ZengAcademy of Medicine SingaporeAnnals, Academy of Medicine, Singapore2972-40662024-12-01531273474110.47102/annals-acadmedsg.2024217Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)Shih Ee GohSaumya Shekhar JamuarSiew Eng ChuaDerrick Chen Kuan YeoJerome Hern Yee GohChee Hon ChinMohamed Zakir KaruvetilEe Lian LeeDaniel Shuen Sheng FungGiles Ming Yee Tan Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements. This review aims to examine recent updates in this field and provide a contextualised summary and recommendations for Asian populations in order to guide healthcare professionals in psychiatric practice. Method: A review of recent literature about current evidence and guidelines surrounding pharmacogenomics in psychiatric practice was carried out with particular attention paid to literature evaluating Asian populations. The Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework was applied. Consensus meetings comprising workgroup psychiatrists from the public and private sectors were held prior to arriving at the key recommendations. Results: Pharmacogenomic testing should be mainly limited to drug-gene pairs with established clinical evidence, such as antidepressants and CYP2C19/CYP2D6. Direct-to-consumer pharmacogenomic panels that assay multiple genes and analyse them via proprietary algorithms, are not presently recommended in Singapore’s psychiatric setting due to inconclusive evidence on clinical outcomes. Conclusion: Pharmacogenomic testing in psychiatry is not recommended as standard clinical practice. Exceptions may include concerns about drug concentrations or potential severe adverse drug reactions. Studies investigating newly identified drug-gene associations, and clinical effectiveness and cost-effectiveness of utilising pharmacogenomic testing in psychiatry is encouraged.https://annals.edu.sg/pharmacogenomics-in-psychiatry-practice-recommendations-from-an-asian-perspective-2024/
spellingShingle Shih Ee Goh
Saumya Shekhar Jamuar
Siew Eng Chua
Derrick Chen Kuan Yeo
Jerome Hern Yee Goh
Chee Hon Chin
Mohamed Zakir Karuvetil
Ee Lian Lee
Daniel Shuen Sheng Fung
Giles Ming Yee Tan
Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
Annals, Academy of Medicine, Singapore
title Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
title_full Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
title_fullStr Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
title_full_unstemmed Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
title_short Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024)
title_sort pharmacogenomics in psychiatry practice recommendations from an asian perspective 2024
url https://annals.edu.sg/pharmacogenomics-in-psychiatry-practice-recommendations-from-an-asian-perspective-2024/
work_keys_str_mv AT shiheegoh pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT saumyashekharjamuar pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT siewengchua pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT derrickchenkuanyeo pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT jeromehernyeegoh pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT cheehonchin pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT mohamedzakirkaruvetil pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT eelianlee pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT danielshuenshengfung pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024
AT gilesmingyeetan pharmacogenomicsinpsychiatrypracticerecommendationsfromanasianperspective2024